Trevi Therapeutics, Inc. logo

Trevi Therapeutics, Inc.

NASDAQ:TRVI

Overview | Financials
Company Name Trevi Therapeutics, Inc.
Symbol TRVI
Currency USD
Price 4
Market Cap 357,462,800
Dividend Yield 0%
52-week-range 1.27 - 4.675
Industry Biotechnology
Sector Healthcare
CEO Ms. Jennifer L. Good
Website https://www.trevitherapeutics.com

An error occurred while fetching data.

About Trevi Therapeutics, Inc.

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritus, chronic cough in patients with

Related Stocks

Aptose Biosciences Inc. logo

Aptose Biosciences Inc.

APTO

0.25 USD

iCAD, Inc. logo

iCAD, Inc.

ICAD

1.78 USD

Axcella Health Inc. logo

Axcella Health Inc.

AXLA

4.58 USD

DURECT Corporation logo

DURECT Corporation

DRRX

0.97 USD

Ardelyx, Inc. logo

Ardelyx, Inc.

ARDX

4.64 USD

Aeglea BioTherapeutics, Inc. logo

Aeglea BioTherapeutics, Inc.

AGLE

12.01 USD

LAVA Therapeutics N.V. logo

LAVA Therapeutics N.V.

LVTX

0.975 USD

Financials

Numbers are in millions USD

Numbers are in millions USD